LPL Financial’s BioLineRX BLRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-2,300
Closed -$19.7K 5367
2024
Q4
$19.7K Hold
2,300
﹤0.01% 5203
2024
Q3
$49.3K Buy
2,300
+250
+12% +$6.87K ﹤0.01% 4999
2024
Q2
$46.7K Sell
2,050
-458
-18% -$12.3K ﹤0.01% 4844
2024
Q1
$112K Hold
2,508
﹤0.01% 4656
2023
Q4
$158K Sell
2,508
-335
-12% -$20.7K ﹤0.01% 4452
2023
Q3
$207K Sell
2,843
-287
-9% -$19.3K ﹤0.01% 4210
2023
Q2
$200K Buy
3,130
+187
+6% +$10.4K ﹤0.01% 4159
2023
Q1
$104K Hold
2,943
﹤0.01% 4200
2022
Q4
$69.4K Buy
2,943
+1,779
+153% +$52.9K ﹤0.01% 4228
2022
Q3
$43K Sell
1,164
-100
-8% -$5.71K ﹤0.01% 4249
2022
Q2
$65K Sell
1,264
-450
-26% -$25K ﹤0.01% 4197
2022
Q1
$117K Sell
1,714
-125
-7% -$8.71K ﹤0.01% 3951
2021
Q4
$150K Buy
1,839
+187
+11% +$19.5K ﹤0.01% 4058
2021
Q3
$182K Hold
1,652
﹤0.01% 4015
2021
Q2
$186K Hold
1,652
﹤0.01% 3923
2021
Q1
$184K Buy
1,652
+580
+54% +$69.7K ﹤0.01% 3788
2020
Q4
$108K Buy
1,072
+650
+154% +$56.8K ﹤0.01% 3668
2020
Q3
$28K Sell
422
-75
-15% -$5.67K ﹤0.01% 3487
2020
Q2
$34K Buy
497
+225
+83% +$15.4K ﹤0.01% 3380
2020
Q1
$14K Buy
+272
New +$21.6K ﹤0.01% 3162
2019
Q3
Sell
-22
Closed -$5K 3298
2019
Q2
$5K Hold
22
﹤0.01% 3270
2019
Q1
$6K Hold
22
﹤0.01% 3177
2018
Q4
$6K Buy
+22
New +$10.6K ﹤0.01% 3060

Other funds holding BLRX

LPL Financial's BLRX Position: Q1 2025 in Review

LPL Financial sold out of BioLineRX (BLRX) in Q1 2025, closing a stake of 2,300 shares — an estimated $19.7K sold.

LPL Financial first reported a position in BLRX in Q4 2018 and held it in 23 quarters. The position peaked at $207K in Q3 2023. 12 funds tracked by Wall St. Rank hold BLRX as of Q1 2025.

  • LPL Financial reported no remaining BioLineRX position as of Q1 2025 after selling out during the quarter.
  • LPL Financial sold 2,300 BioLineRX shares in Q1 2025, an estimated $19.7K.
  • LPL Financial first reported a position in BioLineRX in Q4 2018 and held it in 23 quarters.
  • LPL Financial's BioLineRX position peaked at $207K in Q3 2023.
  • 12 funds tracked by Wall St. Rank held BioLineRX as of Q1 2025.

Based on LPL Financial's 13F filing for Q1 2025, filed 7 May 2025.